I read the CEO's bio and it seems he is very good at partnering/selling companies both which could make us investors a lot of money here should this do the same.
James S. Manuso, Ph.D., MBA
Dr. James S. Manuso was appointed President, Chief Executive Officer and Vice-Chairman of the Board of Directors of RespireRx Pharmaceuticals Inc. in August, 2015. Dr. Manuso also is Chairman and CEO of Talfinium Investments, Inc., an investment entity and financial consultancy, and serves on the board of privately-held, KineMed, Inc. Dr. Manuso formerly served chairman and chief executive officer of Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), formerly SuperGen (NASDAQ:SUPG), from July 2011 until October, 2013, at which time he sold the company to Otsuka Pharmaceuticals for $886MM. Previously, from January 2004 to July 2011, he served as chairman, president and CEO, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001.
Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm. Dr. Manuso was also president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. Dr. Manuso began his career as vice president and Director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as Acting Medical Director.
Previously, he served on the boards of The Biotechnology Industry Organization (BIO) and its Health Section Governing Board, Novelos Therapeutics, Inc. (NVLT:OB; now Cellectar), Merrion Pharmaceuticals Ltd. (MERR:IEX; Dublin, Ireland), Inflazyme Pharmaceuticals, Inc. (IZP-TSE; Vancouver, Canada), Symbiontics, Inc., (sold to BioMarin as ZyStor, Inc. for $110 Million), Montigen Pharmaceuticals, Inc., Quark Pharmaceuticals, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK), where he was chairman.
Dr. Manuso is a biotechnology/pharmaceutical industry CEO and entrepreneur experienced in the foundation, management, financing, governance and sale of start-up, public, private, domestic and international companies with marketed and R&D-stage products. He has extensive investment banking, M&A, general management, and business, financial, corporate, and drug development expertise. Dr. Manuso has served as board chairman, and chairman of audit, governance and nominating, pricing and compensation committees of multiple companies’ boards. He has raised hundreds of millions of dollars for companies and is considered a “financial expert” under Sarbanes-Oxley regulations.
Dr. Manuso was educated in France, Greece and the United States. He earned a B.A. with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology and Genetics from the Graduate Faculty of The New School University where he was a New School Scholar, a Certificate in Health Systems Management from Harvard Business School, and an Executive MBA from Columbia Business School where he was an Equitable Companies Scholar. Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He has taught and lectured at Columbia, New York University, Georgetown, Polytechnic University, and Waseda University (Japan), and he served as a biotechnology consultant to the prime minister of New Zealand. Dr. Manuso has delivered invited addresses at meetings of the American Management Association, the American Medical Association, the Securities Industry Association, the Biotechnology Industry Organization, and many other professional associations. He served previously as Vice President and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society.
AI
Market Data 
Markets 
